Absorption of digoxin from tablets and capsules in subjects with malabsorption syndromes

DICP : the Annals of Pharmacotherapy
W D HeizerJ H Hull

Abstract

The relative steady-state bioavailability of two oral digoxin dosage forms was studied in 17 subjects with malabsorption syndromes. Male subjects received the following treatments in randomized crossover fashion for 14 days: three 0.125-mg digoxin tablets or three 0.1-mg digoxin capsules once daily. Female subjects received digoxin on the same schedule but at two-thirds the dose. Serum and urine samples were collected and analyzed for digoxin by radioimmunoassay, and treatments were compared by evaluating pharmacokinetic parameters. The mean area under the serum concentration versus time curve for tablets (28.1 h.nmol/L [21.9 h.ng/mL]) was smaller (p less than 0.03) than that for capsules (31.1 h.nmol/L [24.3 h.ng/mL]), and the mean maximum serum digoxin concentration for tablets (2.9 nmol/L [2.3 ng/mL]) was lower (p less than 0.02) than that for capsules (4.0 nmol/L [3.1 ng/mL]). There was no difference in cumulative urinary excretion of digoxin between the two treatments. In contrast to previous reports, we observed that digoxin from Lanoxin Tablets appears to be well absorbed in subjects with malabsorption. Nevertheless, these subjects absorbed digoxin from capsules better than from tablets, with the greatest differences occ...Continue Reading

References

Oct 1, 1976·Clinical Pharmacology and Therapeutics·R P JuhlD D Brown
Feb 1, 1975·American Journal of Clinical Pathology·E L Krawitt, W L Beeken
Apr 1, 1977·British Journal of Clinical Pharmacology·B F JohnsonJ French
May 1, 1977·Klinische Wochenschrift·R Brachtel, H J Gilfrich
Dec 1, 1975·Clinical Pharmacology and Therapeutics·G I MallisJ Lindenbaum
Dec 19, 1975·European Journal of Clinical Pharmacology·H OchsH J Dengler
Jun 1, 1976·Clinical Pharmacology and Therapeutics·B F JohnsonG A Sabey
Dec 1, 1973·The Journal of Pharmacy and Pharmacology·E J FraserA B Lipede
Oct 1, 1972·Clinical Science·B BeermannA Rosén
Mar 1, 1974·Circulation·G Levy, M Gibaldi
Jul 26, 1974·European Journal of Clinical Pharmacology·T R Shaw, J E Carless
Jul 29, 1971·The New England Journal of Medicine·W D HeizerS E Goldfinger
Oct 1, 1971·The American Journal of Digestive Diseases·W H Hall, J E Doherty
Dec 1, 1969·The American Journal of Physiology·J H CaldwellN J Greenberger
Dec 1, 1984·Clinical Pharmacology and Therapeutics·B F JohnsonR Marwaha
Oct 1, 1984·Journal of Pharmaceutical Sciences·J A BustrackR H Christenson
Jul 1, 1983·Clinical Pharmacokinetics·T H Lee, T W Smith
Mar 26, 1982·Clinica Chimica Acta; International Journal of Clinical Chemistry·R H ChristensonJ A Bustrack
Oct 1, 1981·The New England Journal of Medicine·J LindenbaumJ R Saha
Jul 1, 1980·The American Journal of Medicine·C D GersonJ Lindenbaum
Jan 12, 1961·The New England Journal of Medicine·G D DRUMMEYC M JONES

Related Concepts

Microcapsules Drug Delivery System
Mapluxin
Malabsorption Syndrome

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Synthetic Genetic Array Analysis

Synthetic genetic arrays allow the systematic examination of genetic interactions. Here is the latest research focusing on synthetic genetic arrays and their analyses.

Congenital Hyperinsulinism

Congenital hyperinsulinism is caused by genetic mutations resulting in excess insulin secretion from beta cells of the pancreas. Here is the latest research.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Epigenetic Memory

Epigenetic memory refers to the heritable genetic changes that are not explained by the DNA sequence. Find the latest research on epigenetic memory here.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Femoral Neoplasms

Femoral Neoplasms are bone tumors that arise in the femur. Discover the latest research on femoral neoplasms here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.